Filtered By:
Drug: Clopidogrel
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1183 results found since Jan 2013.
Single-center experience of endovascular treatment for patients with progressive posterior circulation cerebral infarction exceeding 24 h
CONCLUSION: In patients with progressive posterior circulation cerebral infarction caused by vertebral basilar artery occlusion, ET is effective and safe even if the time from onset to puncture exceeds 24 h.PMID:37719319 | PMC:PMC10505061 | DOI:10.2478/abm-2023-0046
Source: Biomed Res - September 18, 2023 Category: Research Authors: Guangfeng Zhao Xiongjun He Yajie Liu Liang Zhang Kaifeng Li Source Type: research
Potentially Inappropriate Medication Use Among Older Patients with
Diabetes in a Chinese Community
Conclusions Given the higher rate of PIM use among older adults with
diabetes, strategies and interventions targeting this population are needed to
minimize PIM use. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Experimental and Clinical Endocrinology and Diabetes - September 6, 2023 Category: Endocrinology Authors: Zhao, Xingxing Li, Lei Guo, Xiujun Wang, Jianqiang Yan, Yingying Le, Yunyi Tags: Article Source Type: research
CYP2C19 Loss-of-Function Variants Associated with Long-term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
This study aims to determine whether CYP2C19 loss-of-function (LoF) variants were associated with long-term ischemic stroke risk in Chinese primary care patients treated with clopidogrel. Patients treated with clopidogrel were ascertained from a Chinese Electronic Medical Record linked with biobank for a retrospective cohort study. Their medical information was examined for the period from January 2018 to December 2021. Two CYP2C19 major loss of function variants (*2:rs4244285, *3: rs4986893) were genotyped. The clinical outcome was ischemic stroke event. Cox regression analysis was used to evaluate the association between...
Source: Clinical Pharmacology and Therapeutics - August 22, 2023 Category: Drugs & Pharmacology Authors: Peng Wu Ziqing Liu Zijian Tian Benrui Wu Jian Shao Qian Li Zhaoxu Geng Ying Pan Ke Lu Qiang Wang Tao Xu Kaixin Zhou Source Type: research
Ticagrelor versus clopidogrel after intracranial stent angioplasty: a real-world study
ConclusionIn our study involving patients with acute ischemic stroke who had undergone intracranial stenting, aspirin-ticagrelor was not found to be superior to aspirin-clopidogrel in reducing the rate of ischemic vascular events. The risk of bleeding did not differ between the two groups. Aspirin-ticagrelor does not lower total restenosis and symptomatic restenosis risk at follow-up.
Source: Frontiers in Neurology - August 11, 2023 Category: Neurology Source Type: research
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network Meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research
Antiplatelet therapy in Neurointervention
Semin Neurol DOI: 10.1055/s-0043-1771383The aim of this review is to provide an overview of the use of antiplatelet medication in neurointervention, with a focus on the clinical indications for antiplatelet use in both preventing and reducing platelet aggregation. This review will cover current antiplatelet medications, pharmacokinetics, and pharmacodynamics. We will provide an overview of different endovascular devices and discuss the antiplatelet regimes in neurointervention, highlighting gaps in evidence and scope for future studies.Two randomized controlled trials have evaluated antiplatelet use in the setting of acute...
Source: Seminars in Neurology - August 10, 2023 Category: Neurology Authors: Ma, Alice Detaram, Harshil Dharamdasani Steinfort, Brendan Harrington, Tim Nguyen, Thanh N. Abdalkader, Mohamad Siopis, George Bath, Philip M. Dhillon, Permesh Singh Podlasek, Anna Qureshi, Adnan I. Qiu, Zhongming Krishnan, Kailash Tags: Review Article Source Type: research
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research
Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study
Conclusion: In real practice, ticagrelor swi tching among patients with STE-ACS post streptokinase therapy did not differ regarding safety outcomes and composite of efficacy outcomes compared with clopidogrel.
Source: PLoS One - August 4, 2023 Category: Biomedical Science Authors: Phornpaka Ueapornpanith Source Type: research
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis
ConclusionsWhen compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.
Source: American Journal of Cardiovascular Drugs - August 2, 2023 Category: Cardiology Source Type: research
